Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Evidence: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)

Official URL: https://fevir.net/resources/Evidence/55 Version: 1.0.0-ballot3
Standards status: Informative Computable Name: Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY
Other Identifiers: FEvIR Object Identifier: FEvIR Object Identifier#55, OID:2.16.840.1.113883.4.642.40.44.22.58

Copyright/Legal: https://creativecommons.org/licenses/by-nc-sa/4.0/

COVID-19 pneumonia remdesivir vs. placebo 14-day mortality (779 events among 6,744 participants, 3 randomized trials) Risk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect analysis Risk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects analysis

[No data.]